Cannabis Investment
Grow Pharma Joins UK Initiative to Provide Affordable Cannabis-Based Medicines to Patients
Access to Cannabis Medicines Increased with Grow Pharma Joining T21 Initiative.
UK biopharmaceutical company, Grow Pharma, has announced it will be joining the UK charity Drug Science’s T21 initiative, which aims to build an evidence base for the safety and efficacy of cannabis medicines. The move will allow patients to access cannabis-based medicines at a reduced cost, as Grow Pharma becomes one of the industry partners offering discounted private prescriptions for cannabis products.
T21, which was launched in 2019, has over 3,500 patients enrolled on its registry and aims to ultimately increase access to cannabis-based medicines on the NHS. The initiative has already published findings from the data it has collected, highlighting the benefits of cannabis medicines for a wide range of conditions including childhood epilepsy, chronic pain, PTSD, and anxiety.
The addition of Grow Pharma as a partner will allow T21 to extend its formulary, adding more cannabis-based medicines and offering more choice to patients taking part in the study. The move has been welcomed by Drug Science, which said having Grow Pharma on board would help secure the future of the project and allow scientists to collect important data on the effects of cannabis-based medicines.
Pierre van Weperen, Chief Executive of Grow Pharma, said the company’s involvement in the initiative was testament to its mission of making quality cannabis medicines affordable for UK patients. “We have been considering joining for some time and with some of the changes that have been made we feel the time is right. We look forward to working with Drug Science and with the clinics and producers involved in the study,” he said.
The announcement comes after Drug Science revealed a number of changes to the T21 initiative in January, including that the prices of products would now be set by the producers. The charity said it was pleased to have Grow Pharma on board and believed the move would help bring cannabis-based medicines to a wider range of patients in the UK.
